Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction:
Acalabrutinib, marketed under the brand name Acabrunat, is a medication utilized in the treatment of specific cancer types. It falls under the category of Bruton's tyrosine kinase (BTK) inhibitors. Acalabrutinib is specifically sanctioned for treating mantle cell lymphoma (MCL), a subtype of non-Hodgkin's lymphoma.
Mechanism of Action:
Acalabrutinib functions by selectively obstructing the activity of Bruton's tyrosine kinase, an enzyme crucial in the signaling pathways of B-cells. By impeding this enzyme, acalabrutinib aids in suppressing the proliferation and survival of cancerous cells, particularly those associated with MCL.
Uses:
Acalabrutinib is predominantly employed for treating mantle cell lymphoma (MCL) in adult patients who have undergone at least one prior therapy. It is typically prescribed when alternative treatments have proven ineffective or are poorly tolerated. MCL is a malignancy affecting lymphocytes, a type of white blood cell. Acalabrutinib serves to decelerate the advancement of MCL and potentially enhance survival rates among affected individuals.
Benefits of Acalabrutinib (Acabrunat):
Effective treatment for Mantle Cell Lymphoma (MCL): Acalabrutinib has demonstrated notable efficacy in combating MCL, a subtype of non-Hodgkin's lymphoma. It has received approval specifically for patients who have undergone at least one prior therapy. Acalabrutinib can retard the progression of MCL and potentially enhance survival rates.
Selective Targeting of Cancer Cells: Acalabrutinib exclusively targets and inhibits the activity of Bruton's tyrosine kinase (BTK) within cancer cells. By selectively impeding this enzyme, acalabrutinib disrupts the signaling pathways that foster the growth and viability of cancer cells, leading to their suppression.
Oral Administration: Acalabrutinib is formulated as an oral tablet, facilitating convenient administration at home for patients. This obviates the necessity for intravenous infusion or hospital visits, thereby enhancing patient convenience and quality of life.
Potential for Fewer Side Effects Compared to Traditional Chemotherapy: Acalabrutinib's targeted mode of action may entail fewer side effects compared to traditional chemotherapy agents. Although some adverse effects may manifest, they are generally manageable and often less severe in intensity.
Alternative Treatment Option: Acalabrutinib offers an additional treatment avenue for MCL patients who may have exhibited poor responses to alternative therapies or developed intolerance to prior treatments. It presents an alternative strategy for disease management and may contribute to prolonging response duration and overall survival in such patients.